What is Global Soliris Market?
The Global Soliris Market is a vast and dynamic sector that focuses on the distribution and sales of Soliris, a life-saving drug used to treat rare, chronic disorders. Soliris, also known as Eculizumab, is a medication primarily used to treat conditions like paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The market for this drug is global, meaning it spans across various countries and continents, catering to the needs of patients worldwide. The market's size and value are determined by the demand for the drug, the number of patients requiring treatment, and the pricing strategies employed by the pharmaceutical companies. The Global Soliris Market is a crucial component of the healthcare industry, as it directly impacts the availability and accessibility of this vital medication for patients suffering from these rare conditions.
Plasma Exchange, Plasma Infusion in the Global Soliris Market:
Plasma Exchange and Plasma Infusion are two critical procedures in the Global Soliris Market. Plasma Exchange is a process where the plasma in a patient's blood, which may contain harmful substances, is replaced with healthy plasma or a plasma substitute. This procedure is often used for patients with conditions like PNH and aHUS, where the immune system attacks the body's cells. On the other hand, Plasma Infusion involves introducing healthy plasma into a patient's bloodstream to help combat these conditions. Both these procedures are integral to the treatment process and play a significant role in the Global Soliris Market. The market dynamics for these procedures are influenced by factors such as the prevalence of these conditions, advancements in medical technology, and healthcare policies in different regions.
PNH, aHUS, Other in the Global Soliris Market:
The Global Soliris Market plays a pivotal role in treating conditions like PNH, aHUS, and others. PNH is a rare and life-threatening blood disease that leads to the destruction of red blood cells, while aHUS is a condition that causes abnormal blood clots to form in small blood vessels in the kidneys. Soliris is used extensively in the treatment of these conditions due to its effectiveness in inhibiting the immune system's attack on the body's cells. The market for Soliris in treating these conditions is substantial and continues to grow with the increasing awareness and diagnosis of these diseases. The Global Soliris Market ensures that this vital medication reaches the patients who need it, thereby playing a crucial role in global healthcare.
Global Soliris Market Outlook:
Before the COVID-19 pandemic, the China market for Soliris was projected to grow from US$ 43.15 million in 2020 to US$ 105.67 million by 2026, with a Compound Annual Growth Rate (CAGR) of 14.86% during 2021-2026. However, the pandemic has slightly altered these projections. The market for Soliris is now expected to grow from US$ 40.9 million in 2020, a 6.4% change compared to the pre-COVID-19 estimates, to US$ 100.58 million by 2026. The CAGR for this period is expected to be 14.75%. The majority of Soliris usage is for PNH patients, with the proportion in 2019 being 66.85%. These figures highlight the significant impact of the pandemic on the Global Soliris Market and the adjustments made in the market projections.
| Report Metric | Details |
| Report Name | Soliris Market |
| Accounted market size in 2020 | US$ 40.9 million |
| Forecasted market size in 2026 | US$ 100.58 million |
| CAGR | 14.75% |
| Base Year | 2020 |
| Forecasted years | 2024 - 2026 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Alexion |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
